Status:
RECRUITING
International Prospective Registry on Local Treatment Approaches in MLS
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
Radboud University Medical Center
Maastro Clinic, The Netherlands
Conditions:
Myxoid Liposarcoma
Eligibility:
All Genders
18+ years
Brief Summary
To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)
Detailed Description
In order to confirm the promising results of the 36 Gy dose level in the DOREMY trial (NCT02106312) and to compare outcome with other local treatment approaches.
Eligibility Criteria
Inclusion
- Age \> 18 years
- Biopsy proven MLS, including the reciprocal chromosomal translocation t(12;16)(q13;p11)
- ECOG PS 0-2
- Written informed consent to share coded information in this international Registry
Exclusion
- Prior radiotherapy to the target area
- Pregnancy
Key Trial Info
Start Date :
January 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2031
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04699292
Start Date
January 18 2021
End Date
January 1 2031
Last Update
August 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Netherlands Cancer Institute
Amsterdam, Netherlands, 1066CX